Bristol Myers (BMY) Offering Possible 9.89% Return Over the Next 17 Calendar Days

view original post

Bristol Myers’s most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $62.00 short call and a strike $67.00 long call offers a potential 9.89% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $62.00 by expiration. The full premium credit of $0.45 would be kept by the premium seller. The risk of $4.55 would be incurred if the stock rose above the $67.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Bristol Myers

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Mon, 27 Sep 2021 11:06:00 +0000
PRINCETON, N.J., September 27, 2021–U.S. FDA Accepts BMS’s Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal….

3 No-Brainer Stocks to Invest $200 In Right Now
Mon, 27 Sep 2021 09:51:00 +0000
Despite the broad-based S&P 500 declining by a double-digit percentage on 38 separate occasions since the beginning of 1950, each and every one of these pullbacks was eventually erased by a bull-market rally. Operating in a defensive sector means pharmaceutical stocks like Bristol Myers are veritable cash cows.

Is Bristol Myers Squibb Stock a Buy?
Sun, 26 Sep 2021 13:31:00 +0000
Bristol Myers Squibb (NYSE: BMY) stock hasn’t performed very well so far this year. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer’s question about whether or not the big pharma stock is a buy.

Is Now a Good Time to Buy Moderna Stock?
Sun, 26 Sep 2021 12:55:00 +0000
Moderna (NASDAQ: MRNA) has been a huge winner so far this year with its share price more than quadrupling. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer’s question about whether or not now is a good time to buy Moderna stock. Keith Speights: Bhakti asks, “Is it a good time to initiate a position in Moderna?” MRNA is the ticker there.

Why Acceleron Pharma Stock Jumped This Week
Sat, 25 Sep 2021 16:48:33 +0000
Shares of Acceleron Pharma (NASDAQ: XLRN), a mid-cap hematology and pulmonary drugmaker, rose by a healthy 16.2% this week. While the catalyst behind this double-digit jump wasn’t immediately apparent (the company didn’t release any material news during the week), Bloomberg News reported late Friday afternoon that the company is in advanced talks to be acquired for approximately $11 billion, or $180 a share in an all-cash deal. Although Bloomberg couldn’t identify the potential suitor in its initial report, Bristol Myers Squibb (NYSE: BMY) is the obvious candidate.

Be Sociable, Share!

Related Posts